Financial Conflicts of Interest in Propensity Score-Matched Studies Evaluating Biologics and Biosimilars for Inflammatory Bowel Disease
Open Access
- 1 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of the Canadian Association of Gastroenterology
- Vol. 5 (5) , 214-220
Abstract
Propensity score matching (PSM), a statistical technique that estimates a treatment effect by accounting for predictor covariates, has been used to evaluate biologics for inflammatory bowel disease (IBD). Financial conflicts of interest are prevalent in the marketing of biologic medications. It is unclear whether this burden of conflicts is present among authors of PSM studies comparing IBD biologics and biosimilars. This study was aimed to determine the prevalence of financial conflicts of interest among authors of PSM studies evaluating IBD biologics and biosimilars. We conducted a systematic search for PSM studies comparing biologics and biosimilars in IBD treatment. We identified 21 eligible studies. Two independent authors extracted self-declared conflicts from the disclosures section. Each participating author was searched on the Centers for Medicare & Medicaid Services Open Payments to identify payment amounts and undisclosed conflicts. Primary outcome was the prevalence of author conflicts. Secondary analyses assessed for an association between conflict prevalence and reporting of positive outcomes. Among 283 authors, conflicts were present among 41.0% (116 of 283). Twenty-three per cent (27 of 116) of author conflicts involved undisclosed payments. Studies with positive outcomes were significantly more likely to include conflicted authors than neutral studies (relative risk = 2.34, 95% confidence interval: 1.71 to 3.21, P < 0.001). Overall, we found a high burden of undisclosed conflicts among authors of PSM studies comparing IBD biologics and biosimilars. Given the importance of PSM studies as a means for biologic comparison and the potential for undue industry influence from these payments, authors should ensure greater transparency with reporting of industry relationships.Keywords
This publication has 28 references indexed in Scilit:
- The Physician Payment Sunshine ActJAMA, 2015
- Improving the Transparency and Trustworthiness of Subspecialty-Based Clinical Practice GuidelinesMayo Clinic Proceedings, 2014
- Systematic review: the quality of the scientific evidence and conflicts of interest in international inflammatory bowel disease practice guidelinesAlimentary Pharmacology & Therapeutics, 2013
- Promotion of Prescription Drugs to Consumers and Providers, 2001–2010PLOS ONE, 2013
- Does Conflict of Interest Disclosure Worsen Bias?PLOS Medicine, 2012
- Uniform Format for Disclosure of Competing Interests in ICMJE JournalsJAMA, 2010
- On bias and transparency in the development of influential recommendationsCanadian Medical Association Journal, 2006
- Pharmaceutical industry sponsorship and research outcome and quality: systematic reviewBMJ, 2003
- Conflict of Interest in the Debate over Calcium-Channel AntagonistsNew England Journal of Medicine, 1998
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983